What Is Chronic Lymphocytic Leukemia?

This content has been reviewed and approved by

Hagop M. Kantarjian, MD
Chairman & Professor, Leukemia Department
MD Anderson Cancer Center
University of Texas
 

Chronic lymphocytic leukemia (CLL) is a cancer of the blood in which too many lymphocytes, a type of white blood cell, are produced by the bone marrow and by organs of the lymph system. Lymphocytes normally fight infection by making antibodies that attack foreign proteins.

CLL is the most common adult leukemia. About 14,990 new cases of CLL will be diagnosed in the United States in 2010, according to the American Cancer Society. The disease usually occurs in individuals between 65 and 80 years old.

If you have CLL, your lymphocytes are overabundant and many are immature. They are not able to fight infections. They crowd out other blood cells and may collect in blood, bone marrow, lymph tissue, and spleen. CLL is a slowly progressing disease.

CLL can also result in the destruction of red blood cells, leaving you with too few of them.

Like most cancers, early detection and treatment can help control the disease or eliminate it from your body.

This content was last reviewed August 15, 2010 by Dr. Reshma L. Mahtani.
Latest Chronic Lymphocytic Leukemia News
Leukemia patients at greatest risk of listeriosis

December 23, 2011 — NEW YORK (Reuters Health) - People with certain conditions, including leukemia, other cancers and pregnancy, are at the greatest risk of getting sick from the food-borne bacterium Listeria, French researchers report in a new study.

Gene therapy shown to destroy leukemia tumors

August 11, 2011 — LOS ANGELES (Reuters) - Scientists for the first time have used gene therapy to successfully destroy cancer tumors in patients with advanced disease -- a goal that has taken 20 years to achieve.

UK's NICE backs lymphoma drug maintenance therapy

May 24, 2011 — LONDON (Reuters) - Roche's cancer drug MabThera has been recommended for use on Britain's state health service as a maintenance therapy for patients with follicular non-Hodgkin's lymphoma, expanding the market for the medicine.

Select news items provided by Reuters Health